Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Milestone Pharmaceuticals Inc.

NASDAQ: MIST · Life Sciences · 3 alerts · CIK 1408443

Share price
$0.3650Close, Nov 16
Market cap
$45.4M
Shares outstanding
124.5MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Milestone Pharmaceuticals Inc. filings on SEC EDGAR ↗

7:37 AM ET 8-K
Financial Results

Milestone Pharmaceuticals Financial Results

Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.

Term
Q3 2026

“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”

Joseph Oliveto, President and Chief Executive Officer
6:50 AM ET 10-Q
Financial Results

Milestone Pharmaceuticals Q3 2026 Results: Net Loss of $25.8M, Loss Widens

Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.

Key figure
Net loss $25.8M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.